FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer (

FDA Approved
  • FLASCO
  • March 10, 2015

 

FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer

The FDA approval of olaparib occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian cancer. To read more click here.

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO